Sol-Gel Technologies Ltd. Stock Deutsche Boerse AG

Equities

4SG

IL0011417206

Biotechnology & Medical Research

Delayed Deutsche Boerse AG 02:03:07 2024-07-16 am EDT 5-day change 1st Jan Change
0.76 EUR -8.98% Intraday chart for Sol-Gel Technologies Ltd. +3.40% -29.63%
Sales 2024 * 5M 4.59M Sales 2025 * 7.74M 7.1M Capitalization 24.57M 22.55M
Net income 2024 * -23M -21.11M Net income 2025 * -16M -14.69M EV / Sales 2024 * 4.92 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.17 x
P/E ratio 2024 *
-1.06 x
P/E ratio 2025 *
-1.76 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.83%
More Fundamentals * Assessed data
Dynamic Chart
Sol-Gel Technologies CEO Plans to Step Down; New CFO Named MT
Sol-Gel Technologies Ltd. Announces Alon Seri-Levy Step Downs from His Position as CEO, Effective December 31, 2024 CI
Sol-Gel Technologies Ltd. Announces Alon Seri-Levy Step Downs from His Position as Director, Effective December 31, 2024 CI
Sol-Gel Technologies Ltd. Announces Executive Changes CI
Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq MT
Sol-Gel Technologies Ltd. Announces Resignation of Gilad Mamlok as Chief Financial Officer, Effective September 21, 2024 CI
HC Wainwright Adjusts Sol-Gel Technologies Price Target to $6 From $9, Maintains Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sol-Gel Technologies Ltd. and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize Twyneo® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director CI
Transcript : Sol-Gel Technologies Ltd. - Special Call
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study CI
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board CI
HC Wainwright Cuts Sol-Gel Technologies' Price Target to $9 From $12, Keeps Buy Rating MT
More news

Latest transcript on Sol-Gel Technologies Ltd.

1 day-8.98%
1 week+3.40%
Current month-0.65%
1 month-4.40%
3 months-1.94%
6 months-26.21%
Current year-29.63%
More quotes
1 week
0.75
Extreme 0.745
0.84
1 month
0.73
Extreme 0.73
0.84
Current year
0.49
Extreme 0.492
1.32
1 year
0.49
Extreme 0.492
3.36
3 years
0.49
Extreme 0.492
11.90
5 years
0.49
Extreme 0.492
15.50
10 years
0.49
Extreme 0.492
15.50
More quotes
Managers TitleAgeSince
Founder 62 97-10-27
Director of Finance/CFO 56 17-01-31
Chief Operating Officer 48 09-12-31
Members of the board TitleAgeSince
Director/Board Member 56 23-07-25
Director/Board Member 50 18-09-12
Chairman 69 13-12-31
More insiders
Date Price Change
24-07-16 0.76 -8.98%
24-07-15 0.835 +10.60%
24-07-12 0.755 +1.34%
24-07-11 0.745 -8.02%
24-07-10 0.81 +10.20%

Delayed Quote Deutsche Boerse AG, July 16, 2024 at 02:03 am EDT

More quotes
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.882 USD
Average target price
6 USD
Spread / Average Target
+580.27%
Consensus